Liu Peng, Peng Ying, Ding Jinsong, Zhou Wenhu
Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.
Henan Key Laboratory of Biomolecular Recognition and Sensing, Shangqiu Normal University, Shangqiu 476000, China.
Asian J Pharm Sci. 2022 Mar;17(2):177-192. doi: 10.1016/j.ajps.2021.10.003. Epub 2021 Oct 31.
Chemodynamic therapy (CDT) is considered as a promising modality for selective cancer therapy, which is realized via Fenton reaction-mediated decomposition of endogenous HO to produce toxic hydroxyl radical (•OH) for tumor ablation. While extensive efforts have been made to develop CDT-based therapeutics, their efficacy is usually unsatisfactory due to poor catalytic activity limited by tumor microenvironment, such as anti-oxidative systems, insufficient HO, and mild acidity. To mitigate these issues, we have witnessed a surge in the development of CDT-based combinatorial nanomedicines with complementary or synergistic mechanisms for enhanced tumor therapy. By virtue of their bio-imaging capabilities, Fenton metal nanomedicines (FMNs) are equipped with intrinsic properties of imaging-guided tumor therapies. In this critical review, we summarize recent progress of this field, focusing on FMNs for imaging-guided combinatorial tumor therapy. First, various Fenton metals with inherent catalytic performances and imaging properties, including Fe, Cu and Mn, were introduced to illustrate their possible applications for tumor theranostics. Then, CDT-based combinatorial systems were reviewed by incorporating many other treatment means, including chemotherapy, photodynamic therapy (PDT), sonodynamic therapy (SDT), photothermal therapy (PTT), starvation therapy and immunotherapy. Next, various imaging approaches based on Fenton metals were presented in detail. Finally, challenges are discussed, and future prospects are speculated in the field to pave way for future developments.
化学动力学疗法(CDT)被认为是一种有前景的选择性癌症治疗方式,它通过芬顿反应介导内源性过氧化氢(H₂O₂)分解产生有毒的羟基自由基(•OH)来消融肿瘤。尽管人们为开发基于CDT的治疗方法付出了巨大努力,但由于肿瘤微环境的限制,如抗氧化系统、过氧化氢不足和酸度较低导致催化活性较差,其疗效通常不尽人意。为了缓解这些问题,我们见证了基于CDT的组合纳米药物的快速发展,这些药物具有互补或协同机制以增强肿瘤治疗效果。凭借其生物成像能力,芬顿金属纳米药物(FMNs)具备成像引导肿瘤治疗的固有特性。在这篇综述中,我们总结了该领域的最新进展,重点关注用于成像引导组合肿瘤治疗的FMNs。首先,介绍了具有固有催化性能和成像特性的各种芬顿金属,包括铁、铜和锰,以说明它们在肿瘤诊疗中的可能应用。然后,通过结合许多其他治疗手段,包括化疗、光动力疗法(PDT)、声动力疗法(SDT)、光热疗法(PTT)、饥饿疗法和免疫疗法,对基于CDT的组合系统进行了综述。接下来,详细介绍了基于芬顿金属的各种成像方法。最后,讨论了该领域面临的挑战,并对未来前景进行了推测,为未来的发展铺平道路。
Asian J Pharm Sci. 2022-3
J Mater Chem B. 2021-1-14
J Nanobiotechnology. 2021-10-16
Biomater Sci. 2024-9-10
Front Immunol. 2025-2-28
Pharmaceutics. 2024-7-15
J Nanobiotechnology. 2023-11-15
Nan Fang Yi Ke Da Xue Xue Bao. 2023-8-20
Asian J Pharm Sci. 2021-3
Biomater Sci. 2021-4-21
J Appl Toxicol. 2021-9
ACS Biomater Sci Eng. 2020-9-14
Adv Sci (Weinh). 2020-8-16